| 1401 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
21 |
| 1402 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
Denmark
|
65 |
| 1403 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Romania
|
25 |
| 1404 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Italy
|
27 |
| 1405 |
Apheresis |
Allogeneic
|
Polycythaemia Vera
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
61 |
| 1406 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
25 |
| 1407 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
51 |
| 1408 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
70 |
| 1409 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
53 |
| 1410 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Lithuania
|
61 |
| 1411 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Russian Federation
|
49 |
| 1412 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
36 |
| 1413 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
France
|
62 |
| 1414 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
54 |
| 1415 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
74 |
| 1416 |
Apheresis |
Allogeneic
|
NHL Non-Hodgkin Lymphoma
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
49 |
| 1417 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
62 |
| 1418 |
Apheresis |
Allogeneic
|
Myelofibrosis Myeloid Metaplasia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
74 |
| 1419 |
Apheresis |
Allogeneic
|
NHL Non-Hodgkin Lymphoma
|
Hematology
|
2025
|
Standard Therapy
|
Argentine
|
57 |
| 1420 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
56 |
| 1421 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Belgium
|
71 |
| 1422 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Spain
|
59 |
| 1423 |
Apheresis |
Allogeneic
|
Other Myelofibrosis/Myelosclerosis
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
65 |
| 1424 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
14 |
| 1425 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Denmark
|
57 |
| 1426 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
68 |
| 1427 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
51 |
| 1428 |
Apheresis |
Allogeneic
|
Richter Transformation CDLBCC
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
68 |
| 1429 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia-MR
|
Hematology
|
2025
|
Standard Therapy
|
Russian Federation
|
16 |
| 1430 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
63 |
| 1431 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
66 |
| 1432 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
50 |
| 1433 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
38 |
| 1434 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
43 |
| 1435 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
74 |
| 1436 |
Apheresis |
Allogeneic
|
T-cell Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
51 |
| 1437 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
59 |
| 1438 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
66 |
| 1439 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
68 |
| 1440 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
33 |
| 1441 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
48 |
| 1442 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Netherlands
|
66 |
| 1443 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
57 |
| 1444 |
Apheresis |
Allogeneic
|
Chronic Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Belgium
|
56 |
| 1445 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
55 |
| 1446 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
24 |
| 1447 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Italy
|
61 |
| 1448 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
71 |
| 1449 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Canada
|
53 |
| 1450 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
62 |
| 1451 |
Apheresis |
Autologous
|
Mantle Cell Lymphoma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
45 |
| 1452 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
61 |
| 1453 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
32 |
| 1454 |
Apheresis |
Autologous
|
Diffuse Large B-Cell Lymphoma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
62 |
| 1455 |
Apheresis |
Autologous
|
Central Nervous System Lymphoma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
75 |
| 1456 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
70 |
| 1457 |
Cord Tissue |
Autologous
|
Autism
|
Neurology
|
2024
|
Experimental Therapy
|
Romania
|
6 |
| 1458 |
Cord Tissue |
Allogeneic – Related
|
Autism
|
Neurology
|
2024
|
Experimental Therapy
|
Romania
|
6 |
| 1459 |
Cord Tissue |
Autologous
|
Autism
|
Neurology
|
2024
|
Experimental Therapy
|
Romania
|
4 |
| 1460 |
Cord Tissue |
Allogeneic – Related
|
Autism
|
Neurology
|
2024
|
Experimental Therapy
|
Romania
|
6 |
| 1461 |
Cord Tissue |
Allogeneic – Unrelated
|
Degenerative and Traumatic Cartilage
|
Orthopedics
|
2024
|
Experimental Therapy
|
Poland
|
50 |
| 1462 |
Cord Tissue |
Allogeneic – Unrelated
|
Degenerative and Traumatic Cartilage
|
Orthopedics
|
2024
|
Experimental Therapy
|
Poland
|
49 |
| 1463 |
Cord Tissue |
Allogeneic – Unrelated
|
Degenerative and Traumatic Cartilage
|
Orthopedics
|
2024
|
Experimental Therapy
|
Poland
|
58 |
| 1464 |
Cord Tissue |
Allogeneic – Unrelated
|
Graft Versus Host Disease
|
Hematology
|
2024
|
Experimental Therapy
|
Poland
|
7 |
| 1465 |
Cord Tissue |
Allogeneic – Unrelated
|
Graft Versus Host Disease
|
Hematology
|
2024
|
Experimental Therapy
|
Poland
|
15 |
| 1466 |
Cord Tissue |
Allogeneic – Unrelated
|
Ovarian Dysfunction
|
Gynecology
|
2024
|
Experimental Therapy
|
Poland
|
48 |
| 1467 |
Cord Tissue |
Allogeneic – Related
|
Severe Pulmonary Hypertension +Mitral Regurgitation
|
Cardiovascular/Pulmonary
|
2024
|
Experimental Therapy
|
Romania
|
2 |
| 1468 |
Cord Tissue |
Allogeneic – Unrelated
|
Amyotrophic lateral sclerosis
|
Neurology
|
2024
|
Experimental Therapy
|
Poland
|
57 |
| 1469 |
Cord Tissue |
Allogeneic – Unrelated
|
Degenerative and traumatic cartilage damage
|
Orthopedics
|
2024
|
Experimental Therapy
|
Poland
|
68 |
| 1470 |
Cord Tissue |
Allogeneic – Related
|
Autism
|
Neurology
|
2024
|
Experimental Therapy
|
Romania
|
17 |
| 1471 |
Cord Tissue |
Autologous
|
Autism
|
Neurology
|
2024
|
Experimental Therapy
|
Romania
|
7 |
| 1472 |
Cord Tissue |
Allogeneic – Unrelated
|
Degenerative and traumatic cartilage damage
|
Orthopedics
|
2024
|
Experimental Therapy
|
Poland
|
61 |
| 1473 |
Cord Tissue |
Allogeneic – Unrelated
|
Degenerative and traumatic cartilage damage
|
Orthopedics
|
2024
|
Experimental Therapy
|
Poland
|
45 |
| 1474 |
Cord Tissue |
Allogeneic – Unrelated
|
Amyotrophic lateral sclerosis
|
Neurology
|
2024
|
Experimental Therapy
|
Poland
|
56 |
| 1475 |
Cord Tissue |
Allogeneic – Unrelated
|
Graft-versus-host disease
|
Hematology
|
2024
|
Experimental Therapy
|
Poland
|
0 |
| 1476 |
Cord Tissue |
Allogeneic – Unrelated
|
Amyotrophic lateral sclerosis
|
Neurology
|
2024
|
Experimental Therapy
|
Poland
|
39 |
| 1477 |
Cord Tissue |
Allogeneic – Unrelated
|
GvHD
|
Neurology
|
2024
|
Experimental Therapy
|
Poland
|
9 |
| 1478 |
Cord Tissue |
Allogeneic – Unrelated
|
Cerebral palsy
|
Neurology
|
2024
|
Experimental Therapy
|
Poland
|
5 |
| 1479 |
Cord Tissue |
Allogeneic – Unrelated
|
Cerebral palsy
|
Neurology
|
2024
|
Experimental Therapy
|
Poland
|
13 |
| 1480 |
Cord Tissue |
Allogeneic – Unrelated
|
Leukodystrophy
|
Neurology
|
2024
|
Experimental Therapy
|
Poland
|
1 |
| 1481 |
Cord Tissue |
Allogeneic – Unrelated
|
Cerebral Palsy
|
Neurology
|
2024
|
Experimental Therapy
|
Poland
|
7 |
| 1482 |
Cord Tissue |
Allogeneic – Unrelated
|
Leukodystrophy
|
Neurology
|
2024
|
Experimental Therapy
|
Poland
|
1 |
| 1483 |
Cord Tissue |
Allogeneic – Unrelated
|
Cerebellar-spinal ataxia
|
Neurology
|
2024
|
Experimental Therapy
|
Poland
|
35 |
| 1484 |
Cord Tissue |
Allogeneic – Unrelated
|
Leukodystrophy
|
Neurology
|
2024
|
Experimental Therapy
|
Poland
|
1 |
| 1485 |
Cord Tissue |
Allogeneic – Unrelated
|
Cerebral Palsy
|
Neurology
|
2024
|
Experimental Therapy
|
Poland
|
4 |
| 1486 |
Cord Blood |
Autologous
|
Autism
|
Neurology
|
2024
|
Experimental Therapy
|
Romania
|
11 |
| 1487 |
Cord Blood |
Autologous
|
Autism
|
Neurology
|
2024
|
Experimental Therapy
|
Romania
|
10 |
| 1488 |
Cord Blood |
Autologous
|
Autism
|
Neurology
|
2024
|
Experimental Therapy
|
Romania
|
6 |
| 1489 |
Cord Blood |
Autologous
|
Autism
|
Neurology
|
2024
|
Experimental Therapy
|
Romania
|
4 |
| 1490 |
Cord Blood |
Autologous
|
Autism
|
Neurology
|
2024
|
Experimental Therapy
|
Romania
|
5 |
| 1491 |
Cord Blood |
Allogeneic
|
Cerebral Palsy
|
Neurology
|
2024
|
Experimental Therapy
|
Poland
|
3 |
| 1492 |
Cord Blood |
Allogeneic
|
Cerebral Palsy
|
Neurology
|
2024
|
Experimental Therapy
|
Poland
|
7 |
| 1493 |
Cord Blood |
Autologous
|
CP
|
Neurology
|
2024
|
Experimental Therapy
|
Hungary
|
4 |
| 1494 |
Cord Blood |
Autologous
|
Pervasive Developmental Disorder
|
Neurology
|
2024
|
Experimental Therapy
|
Poland
|
3 |
| 1495 |
Cord Blood |
Autologous
|
Pervasive Developmental Disorder
|
Neurology
|
2024
|
Experimental Therapy
|
Poland
|
5 |
| 1496 |
Cord Blood |
Autologous
|
Pervasive developmental disorder
|
Neurology
|
2024
|
Experimental Therapy
|
Poland
|
4 |
| 1497 |
Cord Blood |
Allogeneic – Related
|
fanconi aplastic anemia
|
Hematology
|
2024
|
Standard Therapy
|
Turkey
|
12 |
| 1498 |
Cord Blood |
Autologous
|
Neuroblastoma
|
Neurology
|
2024
|
Standard Therapy
|
Poland
|
4 |
| 1499 |
Cord Blood |
Autologous
|
Pervasive developmental disorder
|
Neurology
|
2024
|
Experimental Therapy
|
Poland
|
9 |
| 1500 |
Cord Blood |
Autologous
|
Autism
|
Neurology
|
2024
|
Experimental Therapy
|
Slovakia
|
4 |